biological source
synthetic
Quality Level
sterility
aseptically filled
Assay
95-105 mg/mL (Iron content)
form
solution
contains
0.5% phenol as preservative
composition
Iron, ~100 mg/mL
color
brown
useful pH range
4 - 6.5
storage temp.
room temp
SMILES string
[Fe].[S](=O)(=O)(O)O
InChI
1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
InChI key
MVZXTUSAYBWAAM-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Application
Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures.
Other Notes
To gain a comprehensive understanding of our extensive range of Dextrans for your research, we encourage you to visit our Carbohydrates Category page.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Carc. 1B - Skin Sens. 1
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Priya Prakash Karmali et al.
Molecular pharmaceutics, 9(3), 539-545 (2012-01-17)
Premature recognition and clearance of nanoparticulate imaging and therapeutic agents by macrophages in the tissues can dramatically reduce both the nanoparticle half-life and delivery to the diseased tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate recognition by liver and spleen macrophages
D L Burns et al.
Nutrition (Burbank, Los Angeles County, Calif.), 11(2), 163-168 (1995-03-01)
Iron dextran was introduced more than 30 yr ago for the parenteral treatment of iron deficiency anemia that is refractory to oral therapy. Iron dextran is a preparation of ferric hydroxide complexed with a low molecular weight fraction of dextran.
Markus R Jahn et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 78(3), 480-491 (2011-03-29)
The treatment of iron deficiency anemia with polynuclear iron formulations is an established therapy in patients with chronic kidney disease but also in other disease areas like gastroenterology, cardiology, oncology, pre/post operatively and obstetrics' and gynecology. Parenteral iron formulations represent
Zachariah DeFilipp et al.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 9(1), 129-132 (2012-08-08)
Iron deficiency is a major postoperative complication of Roux-en-Y gastric bypass surgery. Oral replacement can fail to correct the deficiency. Thus, recourse to parenteral iron administration might be necessary. Our objective was to evaluate the effectiveness and safety of a
V J Kumpf et al.
DICP : the annals of pharmacotherapy, 24(2), 162-166 (1990-02-01)
Parenteral iron therapy is indicated in patients with iron-deficiency anemia associated with conditions that interfere with the ingestion or absorption of oral iron. Replacement doses of iron required to replenish iron stores are based on body weight and the observed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
